Immune Responses in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cells Pulsed with Tumor Lysate

Scandinavian Journal of Immunology

Volumn 70, Issue 5, 2009, Pages 481-489

  Soleimani, A ^a   Berntsen, A ^b   Svane, I M ^b   Pedersen, A E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL PULSED WITH SURVIVIN PEPTIDE; DENDRITIC CELL PULSED WITH TELOMERASE PEPTIDE; DENDRITIC CELLS PULSED WITH TUMOR LYSATE; HLA A2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; UNCLASSIFIED DRUG; VACCINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; MALE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS;

EID: 70350494714     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02322.x     Document Type: Article

References (38)

1. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999 161 : 381 386.
2. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999 22 : 145 154.
3. Verra N, de JD, Bex A et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005 48 : 527 533.
4. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor SP, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009 58 : 1 14.
5. Slingluff CL Jr., Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003 21 : 4016 4026.
6. Berard F, Blanco P, Davoust J et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000 192 : 1535 1544.
7. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006 12 (7 Pt 2 2353s 8s.
8. Berntsen A, Trepiakas R, Wenandy L et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008 31 : 771 780.
9. Svane IM, Pedersen AE, Johansen JS et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; application of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007 56 : 148 599. (accepted for publication).
10. Svane IM, Pedersen AE, Johnsen HE et al. Vaccination with p53 peptide pulsed dendritic cells of patients with advanced breast cancer:report from a phase I study. Cancer Immunol Immunother 2004 53 : 633 641.
11. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002 20 : 621 667.
12. Liu LN, Shivakumar R, Allen C, Fratantoni JC. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol 2008 423 : 139 153.
13. Thumann P, Moc I, Humrich J et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003 277 : 1 16.
14. Tamir A, Basagila E, Kagahzian A et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 2007 56 : 2003 2016.
15. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003 89 : 1172 1179.
16. Salcedo M, Bercovici N, Taylor R et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006 55 : 819 829.
17. Kim JH, Lee Y, Bae YS et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007 125 : 257 267.
18. Avigan DE, Vasir B, George DJ et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007 30 : 749 761.
19. Kuwabara K, Nishishita T, Morishita M et al. Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid 2007 17 : 53 8.
20. Hus I, Schmitt M, Tabarkiewicz J et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8 + T cells as well as CD4 + CD25 + FoxP3 + regulatory T cells toward an antileukemia response. Leukemia 2008 22 : 1007 1017.
21. De VS, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008 14 : 3098 3104.
22. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003 21 : 713 758.
23. Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res 2008 68 : 8456 8464.
24. Mu LJ, Kvalheim G, Sæbøe-Larsen S et al. A Preclinical protocol exploring mRNA-transfected allogeneic monocytes as a potential cancer vaccine. Manuscript in preparation 2009 Jan 1.
25. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999 93 : 1634 1642.
26. Petersson M, Charo J, Salazar-Onfray F et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998 161 : 2099 2105.
27. Seo N, Hayakawa S, Tokura Y. Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 2002 12 : 291 300.
28. Kurte M, Lopez M, Aguirre A et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 2004 173 : 1731 1737.
29. Wigginton JM, Gruys E, Geiselhart L et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001 108 : 51 62.
30. Manetti R, Gerosa F, Giudizi MG et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994 179 : 1273 1283.
31. Manetti R, Parronchi P, Giudizi MG et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993 177 : 1199 1204.
32. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity 1998 8 : 591 599.
33. Marks-Konczalik J, Dubois S, Losi JM et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000 97 : 11445 11450.
34. Carrascal MT, Mendoza L, Valcarcel M et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003 63 : 491 497.
35. Vidal-Vanaclocha F, Mendoza L, Telleria N et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006 25 : 417 434.
36. Takeda K, Tsutsui H, Yoshimoto T et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998 8 : 383 390.
37. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007 178 : 7571 7580.
38. Zhu X, Mulcahy LA, Mohammed RA et al. Interleukin-17 expression by breast cancer associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008 10 : R95.